HOME > TOP STORIES

TOP STORIES

COMMENTARY Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?

November 22, 2019
BUSINESS Evenity Debut, Copycat Entries Set to Jolt Power Map of Japan Osteoporosis Market

November 21, 2019
REGULATORY MHLW to Propose “Special Rule” for Indication Change Re-Pricing

November 21, 2019
BUSINESS Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January

November 20, 2019
BUSINESS Mitsubishi Chemical to Fully Own Mitsubishi Tanabe to Solidify Healthcare Platform

November 19, 2019
ORGANIZATION RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use

November 19, 2019
COMMENTARY Finance Officials, Payers Grow Jittery as Xolair’s Pollen Allergy Nod Looms

November 18, 2019
REGULATORY Will Japan Reinstate Sakigake Status for Aducanumab? Many See It Unlikely

November 15, 2019
BUSINESS Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally

November 14, 2019
REGULATORY Keytruda to Get 17.5% Price Cut in February

November 13, 2019
REGULATORY Keytruda Faces Price Slash on Better-than-Expected Sales

November 12, 2019
REGULATORY Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline

November 11, 2019
REGULATORY Opposition Party Set to Compile HPV Vaccine Proposal by Year-End

November 8, 2019
BUSINESS As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company

November 7, 2019
BUSINESS 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home

November 6, 2019
REGULATORY MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy

November 5, 2019
BUSINESS Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton

November 1, 2019
BUSINESS Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings

October 31, 2019
BUSINESS Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months

October 30, 2019
REGULATORY CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary

October 29, 2019

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…